Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-cell Therapy, in US Adults with B-ALL

Transplantation and Cellular Therapy 2026

View at publisher

Authors: Thomas William LeBlanc, David Bertwistle, Prashant Joshi, Dilip V. Patel, David Huggar

DOI: 10.1016/j.jtct.2025.12.164

Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Economic and Financial Impacts of Cancer Acute Lymphoblastic Leukemia research